Caris Life Sciences (CAI) Gross Margin (2024 - 2026)

Caris Life Sciences' Gross Margin history runs 3 years deep, the most recent figure standing at 99.1% for Q1 2026.

• In Q1 2026, Gross Margin rose 4946.0% year-over-year to 99.1%; the TTM figure through Mar 2026 stood at 57.14% (down 1589.0% YoY), while the FY2025 annual figure was 67.69%, down 2978.0% from the prior year.
• Gross Margin for Q1 2026 stood at 99.1%, up from 13.05% in the prior quarter.
• The five-year high for Gross Margin was 99.1% in Q1 2026, with the low at 13.05% in Q4 2025.
• The 3-year median for Gross Margin is 66.55% (2025), against an average of 66.92%.
• The sharpest annual moves came in 2025 and 2026: Gross Margin sank 8443 bps in 2025, then jumped 4946 bps in 2026.
• Caris Life Sciences' Gross Margin stood at 97.48% in 2024, then slumped by 87 bps to 13.05% in 2025, then surged by 659 bps to 99.1% in 2026.
• Business Quant data shows CAI's Gross Margin at 99.1% in Q1 2026, 13.05% in Q4 2025, and 69.11% in Q3 2025.